NEWS
- ADC Market 2025: Rising Sales and Growing Phase III Pipelines
- Antibody-Degrader Conjugates (DACs): The Next Evolution of Antibody-Drug Conjugates
- The Rise of the TROP2-Directed ADCs for Solid Tumors
- Antibody–Drug Conjugates Targeting MUC1
- From ADCs to ABCs: A New Strategy for High-Capacity Targeted Drug Delivery
- RNA Therapies Update: Donidalorsen FDA Approved, Others Show Promise
- Advances in Antibody-Targeted Lipid Nanoparticles (Ab-LNPs) and Their Emerging Therapeutic Applications
- Antibody-Oligonucleotide Conjugates (AOCs): Recent Advances
- Molecular Glue-Antibody Conjugates (MACs)
- FDA Approval of Semaglutide for MASH - Other Promisiong Pipelines Ahead
